ストックスクリーナーアプリを入手
1.7021
4.21%
-0.0779
前日終値:
$1.78
開ける：
$1.76
24時間の取引高:
4.76M
Relative Volume:
0.58
時価総額：
$510.63M
収益：
$188.87M
当期純損益:
$-400.38M
株価収益率:
-1.1347
EPS:
-1.5
ネットキャッシュフロー:
$-260.90M
1週間 パフォーマンス:
-27.14%
1か月 パフォーマンス:
+21.79%
6か月 パフォーマンス:
+50.88%
1年 パフォーマンス:
-30.41%
1日の値動き範囲:
$1.63
$1.765
1週間の範囲:
$1.63
$2.34
52週間の値動き範囲:
$0.8511
$2.66
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.70 | 534.66M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
125.56 | 217.27B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
99.96 | 146.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.85 | 135.31B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
91.78 | 115.51B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.44 | 47.84B | 5.88B | 1.34B | 577.90M | 2.3455 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
Powered by PacBio: Selected publications from October 2025 - PacBio
Is Pacific Biosciences of California Inc. stock ready for a breakoutQuarterly Trade Summary & Capital Efficiency Focused Ideas - newser.com
Price action breakdown for Pacific Biosciences of California Inc.2025 Volatility Report & Verified Entry Point Signals - newser.com
Will Pacific Biosciences of California Inc. continue its uptrendJuly 2025 Review & Risk Controlled Swing Trade Alerts - newser.com
Will Pacific Biosciences of California Inc. stock recover after recent dropJuly 2025 Spike Watch & Daily Oversold Bounce Ideas - newser.com
Will Pacific Biosciences of California Inc. stock split attract more investorsJuly 2025 Sector Moves & Real-Time Volume Surge Alerts - newser.com
China lifts Illumina ban, clears Pacbio’s Sequel II CNDx - BioWorld MedTech
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y - sharewise.com
Pacific Biosciences of California : PACB Q3 2025 Earnings Prepared Remarks - MarketScreener
Why Pacific Biosciences of California Inc. stock is favored by top institutionsQuarterly Portfolio Report & Real-Time Buy Zone Alerts - newser.com
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2025 Earnings Call Transcript - Insider Monkey
Premarket Movers: WORX, RXST, AFJK, PACB… - RTTNews
Is Pacific Biosciences of California Inc. stock affected by interest rate hikesEarnings Risk Report & Capital Protection Trading Alerts - fcp.pa.gov.br
How to build a custom watchlist for Pacific Biosciences of California Inc.Dividend Hike & Low Risk Investment Opportunities - newser.com
Statistical indicators supporting Pacific Biosciences of California Inc.’s strengthMarket Risk Analysis & Short-Term Trading Alerts - newser.com
Smart tools for monitoring Pacific Biosciences of California Inc.’s price actionJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
Is Pacific Biosciences of California Inc. stock a top pick in earnings season2025 Macro Impact & Free Fast Entry Momentum Trade Alerts - newser.com
Pacific Biosciences: Q3 Earnings Snapshot - CT Insider
PacBio narrows 2025 revenue guidance to $155M-$160M as consumables hit record and clinical focus intensifies - MSN
PACB Q3 Deep Dive: Consumable Strength Offsets Instrument Headwinds, Clinical Expansion in Focus - Yahoo Finance
Ranking Pacific Biosciences of California Inc. among high performing stocks via toolsJuly 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics - sharewise.com
Pacific Biosciences (PACB) Reports Mixed Q3 2025 Earnings - GuruFocus
PacBio Trims Losses And Sets Sights On Cheaper Sequencing - Finimize
Transcript : Pacific Biosciences of California, Inc., Q3 2025 Earnings Call, Nov 05, 2025 - MarketScreener
Can Pacific Biosciences of California Inc. stock resist market sell offs2025 Price Targets & Long-Term Investment Growth Plans - newser.com
Analyzing recovery setups for Pacific Biosciences of California Inc. investorsPortfolio Risk Report & High Return Trade Opportunity Guides - newser.com
Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
Pacific Biosciences (PACB) Q3 2025 Earnings: EPS Loss of $0.13 B - GuruFocus
Is Pacific Biosciences of California Inc. (P09) stock at risk of policy regulationChart Signals & AI Enhanced Market Trend Forecasts - newser.com
Pacific Biosciences of California Inc reports results for the quarter ended September 30Earnings Summary - TradingView
PacBio Q3 revenue falls to $38.4 mln, EPS beats - MarketScreener
PacBio Announces Third Quarter 2025 Financial Results - The Manila Times
PacBio (NASDAQ:PACB) Reports Sales Below Analyst Estimates In Q3 Earnings - Yahoo Finance
PacBio (PACB): HiFi Sequencing Validates Clinical Relevance - GuruFocus
PacBio (PACB): Valuation in Focus After World-First NMPA Approval for Clinical Long-Read Sequencer in China - Yahoo Finance
PacBio (NASDAQ: PACB) announces study detecting all 125 variants across 11 regions - Stock Titan
How resilient is Pacific Biosciences of California Inc. stock in market downturnsQuarterly Portfolio Report & Consistent Return Strategy Ideas - newser.com
Is Pacific Biosciences of California Inc. (P09) stock resilient in recession scenariosWeekly Trade Summary & Stepwise Entry and Exit Trade Signals - newser.com
Does Pacific Biosciences of California Inc. stock trade at a discount to peersEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
5.83%
1.04%
大文字化:
|
ボリューム (24 時間):